BUZZ-Eli Lilly falls after weak Q4 sales forecast for weight-loss drug

Drugmaker Eli Lilly's shares LLY.N fall 3.5% to $769

Eli Lilly expects $1.9 billion in Q4 sales for weight-loss drug Zepbound, compared with estimates of $2.08 billion - LSEG data

Sees Q4 sales of $3.5 billion for diabetes drug Mounjaro, below estimates of $5.35 billion

Co expects 2025 revenue to be in the range of $58 billion to $61 billion, above analysts' estimates of $58.52 billion

Says Q4 2024 revenue is expected to be about $13.5 billion, ~$400 million below the low-end of previous range

Analysts expect Q4 revenue of $13.94 billion

LLY stock rose ~32% in 2024

(Reporting by Sriparna Roy and Christy Santhosh in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))